Reuters logo
7 months ago
BRIEF-Xbrane Biopharma signs agreement with BioAvenir for Spherotide in Israel
December 21, 2016 / 7:19 AM / 7 months ago

BRIEF-Xbrane Biopharma signs agreement with BioAvenir for Spherotide in Israel

1 Min Read

Dec 21 (Reuters) - Xbrane Biopharma AB :

* Signs agreement with BioAvenir for sales and marketing of Spherotide in Israel

* Has signed distribution agreement with BioAvenir for sales and marketing of Spherotide on Israeli market

* Estimates, based on expected price and penetration, that Spherotide has sales potential of about 5 million Swedish crowns ($535,361) annually in Israel

* Xbrane and BioAvenir will share profits from sales of Spheritode in Israel and Xbrane will receive license fee of 1 million crowns divided in upfront and milestone payments

Source text for Eikon:

Further company coverage: ($1 = 9.3395 Swedish crowns) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below